A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [⁶⁴Cu]Cu-NOTA-ch14.18/CHO.

ABSTRACT: Background: The tumor-associated disialoganglioside GD2 is a bona fide immunotherapy target in neuroblastoma and other childhood tumors, including Ewing sarcoma and osteosarcoma. GD2-targeting antibodies proved to be effective in neuroblastoma and GD2-targeting chimeric antigen receptors (CAR)- expressing T cells as well as natural killer T cells (NKTs) are emerging. However, assessment of intra- and intertumoral heterogeneity has been complicated by ineffective immunohistochemistry as well as sampling bias in disseminated disease. Therefore, a non-invasive approach for the assessment and visualization of GD2 expression in-vivo is of upmost interest and might enable a more appropriate treatment stratification. Methods: Recently, [⁶⁴Cu]Cu-NOTA-ch14.18/

SUBMITTER: Trautwein NF 

PROVIDER: S-EPMC10845206 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature